JP2024518434A - 置換スピロ誘導体 - Google Patents

置換スピロ誘導体 Download PDF

Info

Publication number
JP2024518434A
JP2024518434A JP2023568501A JP2023568501A JP2024518434A JP 2024518434 A JP2024518434 A JP 2024518434A JP 2023568501 A JP2023568501 A JP 2023568501A JP 2023568501 A JP2023568501 A JP 2023568501A JP 2024518434 A JP2024518434 A JP 2024518434A
Authority
JP
Japan
Prior art keywords
alkyl
het
mmol
atom
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023568501A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024518434A5 (https=
Inventor
アレシス ジョージズ ケロル，オリヴィア
ダイ，シュエドン
カイ，ウェイ
ウィルヘルムス ジェイ． スーリング，ヨハネス
ファン，リチャオ
リ，ミン
リウ，リアンズ
リウ，インタオ
チン，ルオヘン
ウ，ジアンピン
シュ，ヤンピン
レネ アンジバウド，パトリック
フランス ソランジェ コロンベル，ヘレン
ノエル コンスタンス ピラッテ，イサベル
ソフィー ポンセレト，ヴァージニー
スヴェン クラマー，カーステン
パンデ，ヴィネット
Original Assignee
ヤンセン ファーマシューティカ エヌ．ベー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカ エヌ．ベー． filed Critical ヤンセン ファーマシューティカ エヌ．ベー．
Publication of JP2024518434A publication Critical patent/JP2024518434A/ja
Publication of JP2024518434A5 publication Critical patent/JP2024518434A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2023568501A 2021-05-08 2022-05-06 置換スピロ誘導体 Pending JP2024518434A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2021092256 2021-05-08
CNPCT/CN2021/092256 2021-05-08
PCT/CN2022/091065 WO2022237626A1 (en) 2021-05-08 2022-05-06 Substituted spiro derivatives

Publications (2)

Publication Number Publication Date
JP2024518434A true JP2024518434A (ja) 2024-05-01
JP2024518434A5 JP2024518434A5 (https=) 2025-05-14

Family

ID=76159225

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023568501A Pending JP2024518434A (ja) 2021-05-08 2022-05-06 置換スピロ誘導体

Country Status (9)

Country Link
EP (1) EP4334310A1 (https=)
JP (1) JP2024518434A (https=)
KR (1) KR20240006542A (https=)
CN (1) CN117321049A (https=)
AU (1) AU2022272692A1 (https=)
BR (1) BR112023023154A2 (https=)
CA (1) CA3215379A1 (https=)
MX (1) MX2023013174A (https=)
WO (1) WO2022237626A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024518425A (ja) * 2021-05-08 2024-05-01 ヤンセン ファーマシューティカ エヌ．ベー． 置換スピロ誘導体

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202525813A (zh) 2019-12-19 2025-07-01 比利時商健生藥品公司 經取代之直鏈螺環接衍生物
CN120529900A (zh) 2022-11-24 2025-08-22 奥莱松基因组股份有限公司 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019517548A (ja) * 2016-06-10 2019-06-24 ヴァイティー ファーマシューティカルズ，エルエルシー メニン−ｍｌｌ相互作用の阻害剤
WO2020045334A1 (ja) * 2018-08-27 2020-03-05 大日本住友製薬株式会社 光学活性なアザビシクロ環誘導体
WO2020069027A1 (en) * 2018-09-26 2020-04-02 Kura Oncology, Inc. Treatment of hematological malignancies with inhibitors of menin
JP2020514388A (ja) * 2017-03-24 2020-05-21 クラ オンコロジー，インク． 血液悪性腫瘍およびユーイング肉腫を処置するための方法
CN111297863A (zh) * 2020-03-30 2020-06-19 四川大学华西医院 menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用
JP2024518425A (ja) * 2021-05-08 2024-05-01 ヤンセン ファーマシューティカ エヌ．ベー． 置換スピロ誘導体
JP7554829B2 (ja) * 2019-12-19 2024-09-20 ヤンセン ファーマシューティカ エヌ．ベー． 置換直鎖スピロ誘導体

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102984941B (zh) 2009-09-04 2016-08-17 密执安大学评议会 用于治疗白血病的组合物和方法
WO2014164543A1 (en) 2013-03-13 2014-10-09 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
USRE49687E1 (en) 2014-09-09 2023-10-10 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
HK1246593A1 (zh) 2015-06-04 2018-09-14 Kura Oncology, Inc. 用於抑制menin蛋白与mll蛋白的相互作用的方法及组合物
TWI703150B (zh) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物
AU2016378579A1 (en) 2015-12-22 2018-06-14 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-MLL interaction
PL3429591T3 (pl) 2016-03-16 2023-07-17 Kura Oncology, Inc. Podstawione pochodne tieno[2,3-d]pirymidyny jako inhibitory meniny-mll i metody ich zastosowania
PH12018501955B1 (en) 2016-03-16 2024-01-24 Kura Oncology Inc Bridged bicyclic inhibitors of menin-mll and methods of use
JP6991585B2 (ja) 2016-05-02 2022-01-12 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン メニン阻害剤としてのピペリジン
WO2017207387A1 (en) 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction
WO2018024602A1 (en) 2016-08-04 2018-02-08 Bayer Aktiengesellschaft 2,7-diazaspiro[4.4]nonanes
CA3033020A1 (en) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Fused bicyclic inhibitors of menin-mll interaction
CA3033239A1 (en) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-mll interaction
AU2017326006B2 (en) 2016-09-16 2021-10-28 Vitae Pharmaceuticals, LLC. Inhibitors of the menin-MLL interaction
WO2018109088A1 (en) 2016-12-15 2018-06-21 Janssen Pharmaceutica Nv Azepane inhibitors of menin-mll interaction
WO2018226976A1 (en) 2017-06-08 2018-12-13 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
EP3684361A4 (en) 2017-09-20 2021-09-08 Kura Oncology, Inc. SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHOD OF USING
JP7307729B2 (ja) 2017-12-20 2023-07-12 ヤンセン ファーマシューティカ エヌ．ベー． メニン－ｍｌｌ相互作用のエキソ－アザスピロ阻害剤

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019517548A (ja) * 2016-06-10 2019-06-24 ヴァイティー ファーマシューティカルズ，エルエルシー メニン−ｍｌｌ相互作用の阻害剤
JP2020514388A (ja) * 2017-03-24 2020-05-21 クラ オンコロジー，インク． 血液悪性腫瘍およびユーイング肉腫を処置するための方法
WO2020045334A1 (ja) * 2018-08-27 2020-03-05 大日本住友製薬株式会社 光学活性なアザビシクロ環誘導体
WO2020069027A1 (en) * 2018-09-26 2020-04-02 Kura Oncology, Inc. Treatment of hematological malignancies with inhibitors of menin
JP7554829B2 (ja) * 2019-12-19 2024-09-20 ヤンセン ファーマシューティカ エヌ．ベー． 置換直鎖スピロ誘導体
JP7781961B2 (ja) * 2019-12-19 2025-12-08 ヤンセン ファーマシューティカ エヌ．ベー． 置換直鎖スピロ誘導体
CN111297863A (zh) * 2020-03-30 2020-06-19 四川大学华西医院 menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用
JP2024518425A (ja) * 2021-05-08 2024-05-01 ヤンセン ファーマシューティカ エヌ．ベー． 置換スピロ誘導体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KRIVTSOV, ANDREI V. ET AL.: "Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearr", CANCER CELL, vol. 36(6), JPN7026000507, 2019, pages 660 - 673, ISSN: 0005793442 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024518425A (ja) * 2021-05-08 2024-05-01 ヤンセン ファーマシューティカ エヌ．ベー． 置換スピロ誘導体

Also Published As

Publication number Publication date
CA3215379A1 (en) 2022-11-17
WO2022237626A1 (en) 2022-11-17
AU2022272692A1 (en) 2024-01-04
MX2023013174A (es) 2023-11-30
KR20240006542A (ko) 2024-01-15
BR112023023154A2 (pt) 2024-01-23
EP4334310A1 (en) 2024-03-13
CN117321049A (zh) 2023-12-29

Similar Documents

Publication Publication Date Title
JP7322019B2 (ja) Ｋｒａｓ ｇ１２ｃ阻害剤
CN109715634B (zh) Menin-mll相互作用的稠合二环抑制剂
JP2024521879A (ja) 置換フェニル－１Ｈ－ピロロ［２，３－ｃ］ピリジン誘導体
AU2013290054A1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
HK1203507A1 (en) New indolizine derivatives, method for preparing same and pharmaceutical compositions containing same
JP2024518434A (ja) 置換スピロ誘導体
CN115867346B (zh) 激酶抑制剂
KR20160033224A (ko) 이소인돌린 또는 이소퀴놀린 화합물, 이들의 제조 방법 및 이들을 함유하는 약학적 조성물
JP2024542178A (ja) 縮合イミド誘導体
JP2024518425A (ja) 置換スピロ誘導体
CN110248946B (zh) Menin-MLL相互作用的氮杂环庚烷抑制剂
JP2025541695A (ja) 置換１－フェニル－３，４－ジヒドロピリド［３，４－ｄ］ピリミジン－２－オン誘導体
JP2025540682A (ja) シクロブチル置換二環式化合物
CN117425659A (zh) 哒嗪或被螺环胺取代的1,2,4-三嗪
JP2023514364A (ja) Ｍｃｌ－１の阻害剤としての大環状インドール誘導体
HK40105326A (zh) 取代的螺环衍生物
WO2024220399A1 (en) Pyrazolotriazinecarbonitriles useful as kinase inhibitors
HK40013646A (en) Azepane inhibitors of menin-mll interaction

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250502

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260210